• TG Therapeutics launched a Phase 2 trial of BRIUMVI in adults with treatment-resistant schizophrenia, marking an expansion beyond its multiple sclerosis franchise.
• Open-label, single-arm study targets about 60 patients ages 18-60 who remain symptomatic on standard antipsychotic therapy.
• Primary endpoint is the share of patients achieving at least a 20% reduction in PANSS total score at week 12.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607060730PRIMZONEFULLFEED9757304) on July 06, 2026, and is solely responsible for the information contained therein.